Hong Chang, MD, PhD, FRCPC

Multiple myeloma (MM) is a tumour resulting from clonal expansion of plasma cells and constitutes 10% of hematological malignancies. Survival times in MM are very heterogeneous amongst subgroups with different genetic profiles. The primary focus of my lab is to characterize the genomic aberrations responsible for the initiation and progression of MM, and to identify genetic risk factors that predict clinical outcome in MM patients as well as potential molecular targets for future therapy.

In preclinical studies, we investigate small molecule inhibitors that disrupt p53-MDM2 interactions and induce apoptosis in myeloma cells. We also evaluate novel small molecules that can change the conformation of a mutant p53 to a functional wild-type p53, restoring p53 function as a novel therapeutic strategy, particularly in high-risk MM patients harboring p53 deletions/mutations.
Leukemia. 2018 Apr 24;:
Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H
J Hematol Oncol. 2018 Mar 27;11(1):46
Tremblay-LeMay R, Rastgoo N, Chang H
Ann Thorac Surg. 2017 Dec 06;:
Perrault LP, Kirkwood KA, Chang HL, Mullen JC, Gulack BC, Argenziano M, Gelijns AC, Ghanta RK, Whitson BA, Williams DL, Sledz-Joyce NM, Lima B, Greco G, Fumakia N, Rose EA, Puskas JD, Blackstone EH, Weisel RD, Bowdish ME
J Hematol Oncol. 2017 Oct 26;10(1):169
Abdi J, Rastgoo N, Li L, Chen W, Chang H
Eur J Immunol. 2017 Oct;47(10):1584-1797
Cossarizza A, Chang HD, Radbruch A, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A,...
Eur J Pharm Biopharm. 2017 Sep 05;:
Chen K, Chang HHR, Shalviri A, Li J, Lugtu-Pe JA, Kane A, Wu XY
Leuk Res. 2017 Aug 25;61:39-43
Chen Y, Pourabdollah M, Atenafu EG, Tierens A, Schimmer A, Chang H
Blood. 2017 Aug 31;130(9):1173
Pourabdollah M, Chang H

Pages


 

Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto.